9(10)-Nitrooleate
(Synonyms: 9(10)-Nitrooleic Acid; OA-NO2; 9(10)-nitro-9-trans-Octadecenoic Acid) 目录号 : GC920439(10)-Nitrooleate是一种硝基烯内源性脂质信号分子9-硝基油酸酯的混合物。
Cas No.:1092676-99-7
Sample solution is provided at 25 µL, 10mM.
9(10)-Nitrooleate is a mixture of the nitroalkene endogenous lipid signaling molecules 9-nitrooleate. 9(10)-Nitrooleate is formed by nitration of oleic acid by peroxynitrite, acidified nitrite, and myeloperoxidase in the presence of hydrogen peroxide (H2O2) and nitrite.1 It induces transactivation of peroxisome proliferator-activated receptor γ (PPARγ) or nuclear factor erythroid 2-related factor 2 (Nrf2) in reporter assays using MCF-7 cells when used at concentrations greater than or equal to 0.3 and greater than or equal to 3 ?M, respectively.2 9(10)-Nitrooleate also induces transactivation of PPARγ, PPARδ, or PPARα in reporter assays using CV-1 cells in a concentration-dependent manner.1 It induces adipogenesis in 3T3-L1 preadipocytes and glucose uptake in differentiated 3T3-L1 adipocytes when used at a concentration of 3 ?M. In vivo, 9(10)-nitrooleate (500 ?g/kg every six hours for 24 hours) decreases ischemia-induced increases in plasma levels of blood urea nitrogen, creatinine, and TNF-α and kidney levels of myeloperoxidase (Mpo) and IL-1β and reduces tubular necrosis and tubule dilation in a mouse model of renal ischemia-reperfusion injury.3
References:
[1]. Baker, P.R., Lin, Y., Schopfer, F.J., et al.Fatty acid transduction of nitric oxide signaling. Multiple nitrated unsaturated acid derivatives exist in human blood and urine serve as endogenous peroxisome proliferator-activated receptor ligandsJ. Biol. Chem.280(51)42464-42475(2005).
[2]. Bates, D.J.P., Smitherman, P.K., Townsend, A.L., et al.Nitroalkene fatty acids mediate activation of Nrf2/ARE-dependent and PPARγ-dependent transcription by distinct signaling pathways and with significantly different potenciesBiochemistry50(36)7765-7773(2011).
[3]. Liu, H., Jia, Z., Soodvilai, S., et al.Nitro-oleic acid protects the mouse kidney from ischemia and reperfusion injuryAm. J. Physiol. Renal. Physiol.295(4)F942-F949(2008).
Cas No. | 1092676-99-7 | SDF | |
别名 | 9(10)-Nitrooleic Acid; OA-NO2; 9(10)-nitro-9-trans-Octadecenoic Acid | ||
化学名 | 9-nitro-9E-octadecenoic acid, 10-nitro-9E-octadecenoate | ||
Canonical SMILES | CCCCCCCC/C=C([N+]([O-])=O)\CCCCCCCC(O)=O.CCCCCCCC/C([N+]([O-])=O)=C\CCCCCCCC(O)=O | ||
分子式 | C18H33NO4 ? C18H33NO4 | 分子量 | 654.9 |
溶解度 | Ethanol: Slightly soluble: 0.1-1 mg/ml | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.527 mL | 7.6348 mL | 15.2695 mL |
5 mM | 0.3054 mL | 1.527 mL | 3.0539 mL |
10 mM | 0.1527 mL | 0.7635 mL | 1.527 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet